In brief: ResMed, Meditech, Ventracor
Friday, 04 February, 2005
ResMed (ASX:RMD) shares were up almost 5 per cent today after the company announced record revenue and income results for the quarter ended December 31. Revenue for the quarter was US$103.9 million, a 26 per cent increase over the same quarter last year. Net income for the quarter was US$17.4 million.
Bob Moses has announced that he will not seek re-election as chairman of Meditech (ASX:MTR) at the company's annual general meeting, to be held in March. Meditech intends to appoint a new director by the end of the first quarter.
Ventracor (ASX:VCR) has received permission to begin recruiting patients for the CE Mark trial of its VentrAssist heart pump in Norway through the Rikshopitalet University Hospital in Oslo, one of the largest heart transplant centres in Europe.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
